Skip to Content
Merck
All Photos(1)

Key Documents

F0005000

Famotidine

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

Famotidine, N′-(Aminosulfonyl)-3-([2-(diaminomethyleneamino)-4-thiazolyl]methylthio)propanamidine

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C8H15N7O2S3
CAS Number:
Molecular Weight:
337.45
MDL number:
UNSPSC Code:
41116107
PubChem Substance ID:
NACRES:
NA.24

biological source

synthetic

grade

pharmaceutical primary standard

Agency

EP Reference Standard

API family

famotidine

form

solid

packaging

pkg of 110 mg

manufacturer/tradename

EDQM

storage condition

protect from light

application(s)

pharmaceutical (small molecule)

format

neat

shipped in

ambient

storage temp.

2-8°C

SMILES string

N\C(N)=N\c1nc(CSCCC(=N)NS(N)(=O)=O)cs1

InChI

1S/C8H15N7O2S3/c9-6(15-20(12,16)17)1-2-18-3-5-4-19-8(13-5)14-7(10)11/h4H,1-3H2,(H2,9,15)(H2,12,16,17)(H4,10,11,13,14)

InChI key

XUFQPHANEAPEMJ-UHFFFAOYSA-N

Gene Information

human ... HRH2(3274)

Looking for similar products? Visit Product Comparison Guide

General description

Famotidine is a hydrophilic, cationic, histamine H2 receptor antagonist drug that effectively inhibits gastric acid secretion in humans.

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

This European Pharmacopoeia reference standard is intended for use only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

H2 histamine receptor antagonist; anti-ulcer agent

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Storage Class Code

11 - Combustible Solids

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

H Echizen et al.
Clinical pharmacokinetics, 21(3), 178-194 (1991-09-01)
Famotidine is a potent histamine H2-receptor antagonist widely used in the treatment and prevention of peptic ulcer disease. After intravenous administration the plasma famotidine concentration-time profile exhibits a biexponential decay, with a distribution half-life of about 0.18 to 0.5h and
M C Martinez
The Annals of pharmacotherapy, 33(6), 742-747 (1999-07-20)
To evaluate the use and potential benefit of famotidine in the management of schizophrenia. Clinical literature accessed through MEDLINE (February 1998-October 1998). Key search terms included famotidine, schizophrenia, and histamine. Schizophrenia is a complicated disorder associated with high morbidity if
A N Chremos
Journal of clinical gastroenterology, 9 Suppl 2, 7-12 (1987-01-01)
Famotidine is a competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect in humans is inhibition of gastric acid secretion. Dose-related suppression of basal and stimulated (meal, pentagastrin) gastric acid output has been shown with oral doses of 5-40 mg. The
C W Howden et al.
Clinical therapeutics, 18(1), 36-54 (1996-01-01)
Famotidine is a specific, long-acting histamine2-receptor antagonist. It is indicated for the treatment of duodenal ulcer, gastric ulcer, gastroesophageal reflux disease, and Zollinger-Ellison syndrome. Since its introduction for the treatment of acid-related disorders in 1985, an estimated 18.8 million patients
[Famotidine--a new histamine H2 receptor blockader].
P Ia Grigor'ev et al.
Klinicheskaia meditsina, 69(4), 23-28 (1991-04-01)

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service